Because of in vitro studies, hydroxychloroquine has been evaluated as a preexposure or postexposure prophylaxis for coronavirus disease (COVID-19) and as a possible COVID-19 curative treatment. We report a case of COVID-19 in a patient with sarcoidosis who was receiving long-term hydroxychloroquine treatment and contracted COVID-19 despite adequate plasma concentrations.
All Keywords
【저자키워드】 COVID-19, 2019 novel coronavirus disease, coronavirus disease, severe acute respiratory syndrome coronavirus 2, viruses, respiratory infections, zoonoses, SARS-CoV-2, coronavirus, Hydroxychloroquine, France, sarcoidosis, plasma concentration, 【초록키워드】 Patient, In vitro studies, curative treatment, hydroxychloroquine treatment, Postexposure Prophylaxis, concentrations, evaluated, receiving, adequate plasma,
【저자키워드】 COVID-19, 2019 novel coronavirus disease, coronavirus disease, severe acute respiratory syndrome coronavirus 2, viruses, respiratory infections, zoonoses, SARS-CoV-2, coronavirus, Hydroxychloroquine, France, sarcoidosis, plasma concentration, 【초록키워드】 Patient, In vitro studies, curative treatment, hydroxychloroquine treatment, Postexposure Prophylaxis, concentrations, evaluated, receiving, adequate plasma,